EUVIMEDEUVIMED entdecken
Crossref

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Eoin P Flanagan, Brenda L Banwell, Laura Cacciaguerra, Edgar Carnero Contentti, John J Chen, Rosa Cortese, Giulia Fadda, Kazuo Fujihara, Ruth Geraldes, Yael Hacohen, Ho Jin Kim, Maciej Jurynczyk und 10 weitere

JAMA Neurology · 28.09.2026

DOI: 10.1001/jamaneurol.2026.3196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Neurology, online erschienen am 28.09.2026. Verfasst von Eoin P Flanagan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion distribution, and excluding alternative diagnoses and is a key component of the 2023 MOGAD diagnostic criteria. However, its imaging spectrum and lesion evolution remain underrecognized in practice, and variability in imaging parameters can contribute to delayed diagnosis and suboptimal treatment. Observations This article summarizes the hallmark MRI features of optic nerve, brain, and spinal cord involvement in MOGAD, including key findings from the 2023 diagnostic criteria, supported by illustrative figures and detailed tables. The characteristic evolution of MRI abnormalities in MOGAD is highlighted, including radiologic lag, lesion dynamics during acute attacks, and frequent T2-lesion resolution, contrasting with the persistent lesions typical of MS. A recommended MRI protocol for acute attacks is proposed, and the timing and utility of rebaselining MRI (ie, repeating the MRI to establish a new baseline) after onset are reviewed. The clinical course of MOGAD is of attack-related neuroinflammation evident clinically and radiologically, and asymptomatic radiological activity is rare, suggesting that surveillance MRI has less clinical utility than in MS and less value as a surrogate biomarker in clinical trials. MRI features that differentiate MOGAD from MS and AQP4+NMOSD are summarized and imaging red flags suggestive of alternative diagnoses are highlighted. Finally, emerging advanced imaging, artificial intelligence in MOGAD imaging, and the link between imaging and immunopathogenesis are reviewed. Conclusions and Relevance MRI is central to MOGAD evaluation, and recognition of the characteristic imaging features and lesion dynamics outlined in this review can aid diagnosis. Application of the standardized MRI protocol summarized here can optimize use in clinical practice and promote harmonization across research studies. Future imaging and artificial intelligence applications may improve diagnosis, disease monitoring, and understanding of MOGAD pathogenesis.

Autor:innen und Institutionen

  • Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland.
  • Neuroimmunology Unit, Department of Neurosciences, Hospital Aleman, Buenos Aires, Argentina.
  • CENRos, Neuroimmunology Clinic, INECO Neurociencias Oroño, Rosario, Argentina.
  • Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.

Zitieren

APA

Flanagan, E. P., Banwell, B. L., Cacciaguerra, L., Carnero Contentti, E., Chen, J. J., Cortese, R., Fadda, G., Fujihara, K., Geraldes, R., Hacohen, Y., Kim, H. J., Jurynczyk, M., Levy, M., Mankad, K., Marignier, R., Messina, S., Paul, F., Ramanathan, S., Rovira, A., …, & Palace, J. (2026). MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.3196

Vancouver

Flanagan EP, Banwell BL, Cacciaguerra L, Carnero Contentti E, Chen JJ, Cortese R, et al. MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.3196

BibTeX
@article{Flanagan2026,
  author = {Flanagan, Eoin P and Banwell, Brenda L and Cacciaguerra, Laura and Carnero Contentti, Edgar and Chen, John J and Cortese, Rosa and Fadda, Giulia and Fujihara, Kazuo and Geraldes, Ruth and Hacohen, Yael and Kim, Ho Jin and Jurynczyk, Maciej and Levy, Michael and Mankad, Kshitij and Marignier, Romain and Messina, Silvia and Paul, Friedemann and Ramanathan, Sudarshini and Rovira, Alex and Sechi, Elia and Tenembaum, Silvia and Palace, Jacqueline},
  title = {MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease},
  journal = {JAMA Neurology},
  year = {2026},
  doi = {10.1001/jamaneurol.2026.3196}
}
Kostenlos starten →